SCHEMBL17899864

SCHEMBL17899864

CCOC(=O)C(C)(C)Oc1ccc2ccccc2c1-c1ccc(C#N)c2ccccc12

nearest known ligand 0.75

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SLC22A12 Q96S37 7/20 0.75
▸ FBP1 P09467 5/20 0.41
▸ KDM4E B2RXH2 2/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ IMPDH2 P12268 1/20 0.38
▸ IMPDH1 P20839 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ ABCB11 O95342 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ PMP22 Q01453 1/20 0.37
▸ PPARA Q07869 1/20 0.37
▸ MAPT P10636 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17899873 0.86 SLC22A12 (1.00) SLC22A12KDM4EIMPDH2IMPDH1ALDH1A1
SCHEMBL28388162 0.85 SLC22A12 (0.54) SLC22A12FBP1KDM4ETDP1ALDH1A1
SCHEMBL17899889 0.80 SLC22A12 (0.74) SLC22A12KDM4ETDP1MAPT
SCHEMBL19435574 0.74 IMPDH2 (0.64) SLC22A12KDM4EIMPDH2IMPDH1ALDH1A1
SCHEMBL9037321 0.74 TSHR (0.46) SLC22A12FBP1HSD17B10ABCB11CYP1A2
SCHEMBL21350534 0.72 SLC22A12 (0.56) SLC22A12FBP1
SCHEMBL9035224 0.71 TSHR (0.46) FBP1IMPDH2HSD17B10ABCB11CYP1A2
SCHEMBL28386432 0.69 SLC22A12 (0.53) SLC22A12KDM4ETDP1PPARAMAPT
SCHEMBL19547904 0.69 SLC22A12 (0.60) SLC22A12IMPDH2IMPDH1MAPT
SCHEMBL19435545 0.69 SLC22A12 (0.57) SLC22A12KDM4EIMPDH2IMPDH1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3241822-B1 URAT1 INHIBITOR NIPPON CHEMIPHAR CO (JP) 2021-03-24 — — EP claimed
US-10173990-B2 URAT1 inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2019-01-08 — — US claimed
EP-3241822-A1 URAT1 INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2017-11-08 — — EP claimed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 — — US claimed
EP-3241822-B1 URAT1 INHIBITOR NIPPON CHEMIPHAR CO (JP) 2021-03-24 — — EP disclosed
US-10173990-B2 URAT1 inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2019-01-08 — — US disclosed
US-10173990-B2 URAT1 inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2019-01-08 — — US disclosed
EP-3241822-A1 URAT1 INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2017-11-08 — — EP disclosed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 — — US disclosed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 — — US disclosed
WO-2016108282-A1 URAT1 INHIBITOR 日本ケミファ株式会社 2016-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170290795-A1 URAT1 INHIBITOR SLC10A1, XDH, URB2 SLC22A12 512/4885FBP1 1404/4885KDM4E 2799/4885
US-10173990-B2 URAT1 inhibitor SLC10A1, XDH, URB2 SLC22A12 500/4885FBP1 1486/4885KDM4E 2791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback